Current research

A-BRAVE

https://clinicaltrials.gov/ct2/show/NCT02926196.

RHM CAN 1416 PI: Dr E Copson Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-l1 antibody Avelumab: A phase III randomized trial

Add-Aspirin

http://www.addaspirintrial.org/

RHMCAN 1055 PI: Dr T Iveson. A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

CANDO-1

RHM CAN 1198 PI: Prof R Cutress. A cohort study to investigate body composition in women with breast cancer – uses medical Body Composition Analyser.

Screening versus Symptomatic patients and a control group

CANDO-3

RHM CAN 1491 PI: Dr E Copson. Body composition and chemotherapy toxicity in women with early breast cancer – uses medical Body Composition Analyser

LORIS

https://www.birmingham.ac.uk/research/crctu/trials/loris/index.aspx

RHM CAN 1003 PI: Dr M Stahnke. A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS)

NOSTRA

https://www.birmingham.ac.uk/research/crctu/trials/NOSTRA-Feas/index.aspx

RHM CAN 1481 PI: Prof R Cutress. NOSTRA-Feasibility Study: A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies

OPTIMA

http://www.optimabreaststudy.com/

RHM CAN1171 PI: Dr J Bradbury. Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis.

PARTNER

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-olaparib-with-chemotherapy-for-early-breast-cancer-partner#undefined

RHM CAN 1255 PI: Dr E Copson Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA

PlasmaMATCH

https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/clinical-trials/plasmamatch

RHM CAN 1265 PI: Dr E Copson The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices

A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening

VIOLETTE

https://clinicaltrials.gov/ct2/show/NCT03330847

RHM CAN 1355 PI: Dr E Copson. A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)